No Data
No Data
Anbiping (688393.SH)'s net profit of 7.99 million yuan in the first quarter increased 2.17% year over year
Gelonghui, April 29丨An Biping (688393.SH) announced that in the first quarter of 2024, the company's revenue was 101 million yuan, up 11.82% year on year; net profit attributable to shareholders of listed companies was 7.99 million yuan, up 2.17% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4.8 million yuan, up 78.59% year on year.
Guangzhou LBP Medicine Science & Technology's (SHSE:688393) Shareholders Have More To Worry About Than Only Soft Earnings
The market rallied behind Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) stock, leading do a rise in the share price after its recent weak earnings report. We think that shareh
LBP Medicine Scraps Convertible Bonds Issuance Plans
Guangzhou LBP Medicine Science & Technology (SHA:688393) withdrew plans to issue convertible bonds, the company said in its filing on the Shanghai Stock Exchange. The Chinese diagnostic product manufa
An Biping (688393.SH): Net profit in 2023 fell 6.18% year on year, and plans to pay 10 to 1.5 yuan
Gelonghui, April 22丨An Biping (688393.SH) released its 2023 annual report. Operating revenue for the reporting period was 497 million yuan, down 1.99% year on year; net profit attributable to shareholders of listed companies was 40.572 million yuan, down 6.18% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 353.13,800 yuan, down 13.74% year on year; basic earnings per share were 0.43 yuan. The company plans to distribute a cash dividend of 1.5 yuan (tax included) for every 10 shares to all shareholders.
LBP Medicine Gets Certificate for HER2 Antibody Reagent
Guangzhou LBP Medicine Science & Technology (SHA:688393) received a device registration certificate for its HER2 antibody reagent from China's National Medical Products Administration, according to th
Anbiping: Obtaining a medical device registration certificate for HER2 antibody reagents
An Biping announced on the evening of April 18 that the company recently received a “Medical Device Registration Certificate” for the HER2 antibody reagent issued by the State Drug Administration. This reagent is an immunohistochemical platform used to qualitatively detect HER2 antigen in breast cancer patients, and a registration certificate for trastuzumab concomitant diagnostic testing.
No Data